Compare BridgeBio Pharma Inc (BBIO) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Exxon Mobil Corporation — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while Exxon Mobil Corporation trades at $145.04 (market cap $601.39B). The key difference: Exxon Mobil Corporation is far larger — about 36.5× BridgeBio Pharma Inc's market cap, and Exxon Mobil Corporation pays a 2.84% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | XOM | |
|---|---|---|
Market Cap | $16.46B | $601.39B |
Sector | Health | Energy |
52-Week High | $90.17 | $171.52 |
52-Week Low | $44.81 | $105.83 |
Enterprise Value | $18.02B | $640.62B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
ExxonMobil (XOM) trades at $145.09, up 4.51% today, with strong technical momentum and bullish moving average signals. The company maintains solid profitability with 7.76% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Exxon's Permian Basin advantages and potential oil price spikes to $150-160 per barrel, while the company relocates its headquarters to Texas for business-friendly policies.
XOM presents a compelling investment case with analyst consensus target of $169.30 (17% upside), though risks include declining revenue trends (2025: $323.9B vs 2022: $398.7B) and oil price volatility. The stock's 24.33 P/E appears reasonable given operational strength, but investors should monitor execution on production targets and global energy market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
